background
emerg
influenza
pandem
estim
sever
probabl
sever
outcom
hospit
infect
public
health
prioriti
mani
influenza
infect
subclin
serosurveil
need
allow
reliabl
realtim
estim
infect
attack
rate
iar
sever
method
find
test
sera
collect
first
wave
pandem
hong
kong
use
viral
microneutr
estim
iar
infectionhospit
probabl
ihp
serial
crosssect
serolog
data
hospit
data
serolog
data
avail
weekli
real
time
would
obtain
reliabl
ihp
estim
wk
wk
wk
epidem
peak
individu
age
ratio
iar
preexist
seropreval
decreas
age
major
determin
timeli
reliabl
estim
began
serosurveil
wk
commun
transmiss
confirm
specimen
per
week
individu
age
respect
would
obtain
reliabl
ihp
estim
age
group
wk
peak
old
even
specimen
per
week
would
gener
reliabl
estim
peak
ratio
iar
preexist
seropreval
age
group
low
perform
serial
crosssect
serosurveil
substanti
deterior
test
specif
near
preexist
seropreval
near
zero
potenti
limit
could
mitig
choos
higher
titer
cutoff
seroposit
epidem
doubl
time
longer
serial
crosssect
serosurveil
specimen
per
week
would
yield
reliabl
estim
iar
reach
around
conclus
serial
crosssect
serolog
data
togeth
clinic
surveil
data
allow
reliabl
realtim
estim
iar
sever
emerg
pandem
serosurveil
pandem
consid
one
lesson
learn
influenza
pandem
need
rapid
reliabl
estim
transmiss
sever
probabl
sever
outcom
hospit
death
infect
novel
viru
crucial
public
health
plan
effect
commun
public
earli
effort
hamper
limit
data
initi
estim
basic
reproduct
number
rang
consist
find
countri
subsequ
affect
initi
estim
casefat
probabl
appear
substanti
overestim
june
establish
comprehens
serolog
survey
hong
kong
facilit
enhanc
local
laboratori
capac
develop
sinc
epidem
sever
acut
respiratori
syndrom
hong
kong
use
extens
laboratori
test
among
hospit
respiratori
ill
throughout
influenza
pandem
previous
report
infect
attack
rate
iar
sever
estim
use
serolog
data
collect
immedi
first
wave
pandem
hong
kong
companion
studi
use
pair
sera
collect
cohort
estim
iar
sever
profil
hong
kong
show
specimen
collect
around
peak
epidem
larger
cohort
could
yield
reliabl
sever
estim
paper
use
avail
serial
crosssect
serolog
data
investig
soon
would
obtain
reliabl
estim
iar
infectionhospit
probabl
ihp
probabl
hospit
infect
serolog
data
avail
weekli
realtim
epidem
unfold
illustr
principl
serial
crosssect
serosurveil
conduct
extens
comput
simul
assess
expect
perform
logist
requir
futur
pandem
studi
organ
follow
first
describ
convolutionbas
method
realtim
estim
iar
ihp
clinic
surveil
serial
crosssect
serolog
data
method
use
estim
incid
england
next
retrospect
appli
method
hospit
serolog
data
sequenti
comput
realtim
estim
ihp
iar
would
obtain
epidem
unfold
estim
number
specimen
would
requir
order
obtain
reliabl
estim
ihp
iar
wk
epidem
peak
final
conduct
comput
simul
hypothet
pandem
scenario
analyz
perform
serial
crosssect
serosurveil
depend
characterist
serolog
test
sensit
specif
throughput
lead
time
titer
cutoff
preexist
seropreval
epidem
dynam
basic
reproduct
number
gener
time
natur
histori
antibodi
respons
kinet
goal
provid
oper
guidelin
implement
serial
crosssect
serosurveil
futur
pandem
influenza
infecti
diseas
agestratifi
data
daili
number
virolog
confirm
outpati
consult
hospit
intens
care
unit
admiss
death
associ
april
novemb
provid
eflu
databas
hong
kong
hospit
author
begin
may
patient
admit
acut
respiratori
ill
routin
underw
laboratori
test
viru
laboratori
result
avail
typic
within
h
notif
central
databas
typic
within
local
transmiss
identifi
midjun
contain
effort
enforc
june
requir
laboratoryconfirm
case
hospit
isol
regardless
diseas
sever
therefor
surveil
data
june
onward
use
analysi
studi
focus
estim
ihp
defin
probabl
infect
case
necessarili
symptomat
requir
hospit
earlier
public
call
quantiti
casehospit
rate
revis
terminolog
avoid
confus
probabl
hospit
infect
symptom
eg
assum
ihp
constant
june
onward
june
june
test
serum
sampl
blood
donor
age
hospit
outpati
age
particip
commun
pediatr
cohort
studi
age
descript
studi
design
preliminari
analys
subset
sera
collect
immedi
first
wave
found
text
sera
test
antibodi
respons
viral
microneutr
mn
definit
mn
titer
previou
public
current
studi
slightli
differ
latest
world
health
organ
recommend
publish
follow
previou
convent
mn
titer
denot
take
account
final
dilut
result
mix
serum
dilut
viru
latest
manual
laboratori
diagnosi
recommend
viru
titer
denot
initi
serum
dilut
alon
effect
mn
titer
current
studi
need
halv
compar
follow
latest
recommend
eg
veguilla
et
al
use
estim
antibodi
respons
kinet
paramet
current
studi
see
text
detail
defin
seroposit
mn
antibodi
titer
seropreval
proport
individu
seroposit
agespecif
seropreval
three
group
particip
larg
similar
across
time
first
wave
figur
estim
iar
among
serolog
studi
differ
countri
use
differ
sampl
scheme
quit
similar
build
model
illustr
principl
serial
crosssect
serosurveil
aggreg
seropreval
data
three
group
particip
though
acknowledg
aggreg
gener
welljustifi
term
repres
specimen
collect
june
collect
use
estim
seropreval
june
serolog
data
june
novemb
group
weekli
batch
collect
time
batch
set
averag
collect
time
constitu
ie
weight
number
sampl
day
summari
serolog
data
use
studi
compris
sampl
collect
old
novemb
use
convolutionbas
method
obtain
realtim
estim
ihp
iar
serial
crosssect
serolog
data
hospit
data
method
use
estim
incid
england
schemat
method
shown
figur
method
requir
know
cumul
distribut
function
time
ill
onset
hospit
f
hosp
cumul
distribut
function
time
ill
onset
seroposit
f
seropo
proport
infect
eventu
becam
seroposit
h
principl
directli
observ
pandem
surveil
basic
algorithm
method
follow
time
epidem
use
f
hosp
deconvolut
daili
hospit
h
h
obtain
unscal
incid
daili
number
infect
curv
ihp
known
true
incid
curv
estim
divid
ihp
step
skip
actual
onset
date
hospit
case
known
use
f
seropo
construct
estim
seropreval
curv
b
b
unscal
incid
curv
p
true
prepandem
seropreval
fit
estim
seropreval
curv
b
b
serial
crosssect
serolog
data
find
valu
ihp
p
maxim
follow
likelihood
function
product
time
crosssect
serolog
data
avail
compon
binomi
probabl
get
x
seroposit
test
n
sampl
collect
time
true
seropreval
b
iar
estim
divid
unscal
incid
curv
maximum
likelihood
estim
mle
ihp
basic
algorithm
sensit
specif
serolog
test
assum
method
extend
incorpor
imperfect
sensit
specif
tempor
variat
ihp
eg
weekend
season
effect
differ
titer
cutoff
seroposit
see
text
gener
algorithm
take
account
factor
note
sensit
specif
refer
probabl
result
serolog
test
posit
neg
serum
specimen
truli
seroposit
seroneg
regardless
whether
seroposit
due
preexist
crossreact
antibodi
antibodi
gener
recent
pandem
infect
therefor
definit
sensit
specif
differ
recent
step
statist
infer
ihp
true
seropreval
preexist
seropreval
find
best
valu
ihp
preexist
seropreval
fit
seropreval
curv
serial
crosssect
serolog
data
use
maximum
likelihood
divid
unscal
incid
estim
ihp
obtain
incid
unscal
seropreval
ihp
relat
public
perform
serolog
assay
sensit
defin
probabl
posit
serolog
result
among
infect
individu
specif
probabl
neg
serolog
result
among
uninfect
individu
retrospect
appli
convolutionbas
method
data
made
follow
model
specif
iar
ihp
estim
follow
age
group
eas
comparison
previou
studi
sensit
specif
serolog
test
mn
titer
serolog
result
batch
specimen
avail
last
sampl
batch
collect
likelihood
function
step
basic
algorithm
defin
averag
collect
time
specimen
contain
ith
batch
simplic
ignor
delay
infect
ill
onset
around
incorpor
delay
would
essenti
shift
estim
incid
curv
left
length
delay
upperbound
agespecif
ihp
time
cumul
number
hospit
divid
cumul
number
confirm
case
time
age
group
similarli
lowerbound
cumul
number
hospit
divid
size
age
group
cumul
distribut
function
time
ill
onset
hospit
f
hosp
base
hospit
case
whose
onset
date
avail
clinic
surveil
data
figur
proport
infect
individu
eventu
becam
seroposit
h
cumul
distribut
function
time
ill
onset
seroposit
f
seropo
estim
use
publish
data
kinet
antibodi
respons
among
laboratoryconfirm
case
unit
state
simplifi
analysi
assum
f
seropo
distribut
mean
seropo
construct
likelihood
l
h
seropo
antibodi
respons
data
result
almost
ident
use
instead
see
text
detail
result
mle
h
seropo
howev
given
modest
sampl
size
studi
estim
associ
signific
uncertainti
figur
incorpor
uncertainti
realtim
estim
iar
ihp
modifi
convolutionbas
method
estim
ihp
p
h
f
seropo
simultan
redefin
likelihood
product
l
ihp
p
step
l
h
seropo
premis
antibodi
respons
data
similar
sampl
size
precis
could
obtain
realtim
earli
phase
pandem
serolog
followup
first
virolog
confirm
case
defin
full
model
estim
ihp
p
h
f
seropo
obtain
full
set
hospit
serial
crosssect
serolog
data
ie
novemb
model
iar
estim
would
accur
ihp
estim
accur
concis
focu
latter
present
result
evalu
reliabl
sequenti
realtim
estim
ihp
use
full
model
refer
comparison
ie
assum
full
model
gave
accur
estim
true
ihp
context
regard
realtim
ihp
estim
reliabl
mle
differ
mle
full
model
interquartil
rang
iqr
less
three
time
mle
assess
logist
requir
expect
perform
serial
crosssect
serosurveil
futur
pandem
first
estim
number
specimen
would
allow
reliabl
estim
ihp
midaugust
wk
epidem
peak
assum
incid
seropreval
curv
full
model
accur
simul
stochast
realiz
serial
crosssect
serosurveil
prepandem
specimen
use
estim
seropreval
june
specimen
collect
test
everi
week
start
fourth
week
juli
wk
commun
transmiss
confirm
sequenti
realtim
estim
ihp
comput
use
convolutionbas
method
search
smallest
valu
age
group
would
yield
reliabl
estim
ihp
midaugust
next
conduct
simul
hypothet
epidem
scenario
order
analyz
gener
behavior
serial
crosssect
serosurveil
first
consid
susceptibleinfectedremov
epidem
dynam
basic
reproduct
number
r
mean
gener
time
g
ihp
probabl
distribut
infecti
durat
mean
g
w
w
w
number
erlang
stage
assum
probabl
distribut
f
hosp
model
figur
assum
sera
collect
time
uniformli
distribut
symptom
onset
avail
estim
h
f
seropo
model
specif
number
see
text
detail
simul
serial
crosssect
serosurveil
serum
sampl
per
week
start
infect
seed
popul
million
delay
seed
meant
reflect
time
need
develop
reliabl
serolog
assay
set
serosurveil
oper
simul
follow
scenario
studi
effect
sensit
specif
serolog
test
preexist
seropreval
altern
titer
cutoff
seroposit
sensit
specif
preexist
seropreval
h
f
seropo
mean
ie
mle
us
antibodi
respons
data
b
scenario
sensit
c
scenario
specif
scenario
preexist
seropreval
e
scenario
higher
titer
cutoff
seroposit
h
mean
f
seropo
increas
final
investig
depend
epidem
dynam
simul
serial
crosssect
serosurveil
epidem
scenario
randomli
gener
use
latinhypercub
sampl
follow
paramet
space
r
g
ihp
probabl
distribut
infecti
durat
erlangk
k
popul
size
million
h
f
seropo
gamma
mean
coeffici
variat
standard
deviat
divid
mean
mean
standard
deviat
f
seropo
includ
statist
infer
ie
relax
previou
assumpt
f
seropo
epidem
scenario
compar
perform
serosurveil
follow
oper
condit
serosurveil
begun
seed
specimen
per
week
serosurveil
begun
seed
specimen
per
week
studi
protocol
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
agespecif
seropreval
curv
full
model
provid
reason
good
fit
serial
crosssect
serolog
data
figur
except
first
wk
septemb
old
period
seropreval
full
model
substanti
higher
proport
seroposit
sera
data
discrep
like
due
small
number
serum
specimen
avail
wk
agespecif
ihp
final
iar
full
model
mostli
similar
previou
estim
base
preand
postfirstwav
sera
tabl
largest
discrep
final
iar
old
full
model
higher
previou
estim
howev
expect
inclus
outpati
sera
full
model
previou
estim
note
previou
studi
text
postfirstwav
seropreval
outpati
substanti
higher
blood
donor
age
group
henc
higher
final
iar
full
model
serolog
data
avail
weekli
real
time
reliabl
estim
ihp
would
avail
earli
octob
old
earli
septemb
old
midoctob
old
figur
time
point
correspond
wk
wk
wk
epidem
peak
old
reliabl
estim
ihp
would
avail
peak
number
serum
specimen
small
collect
sera
begin
wk
peak
age
group
old
reliabl
estim
ihp
would
avail
first
wave
almost
final
iar
compar
magnitud
preexist
seropreval
age
group
signaltobackground
ratio
small
requir
larger
number
sera
rel
averag
specimen
per
week
studi
see
figur
order
accur
detect
increas
seropreval
gener
pandem
infect
see
analysi
discuss
sequenti
realtim
estim
ihp
exhibit
follow
pattern
mle
zoom
correct
order
magnitud
upon
first
crosssect
serolog
data
seropreval
appar
prepandem
level
confid
interv
widen
upon
crosssect
serolog
data
seropreval
lower
uptod
estim
model
eg
statist
nois
associ
sampl
begun
weekli
serosurveil
fourth
week
juli
would
need
around
specimen
per
week
old
old
old
order
obtain
reliabl
estim
ihp
age
group
midaugust
figur
old
even
prohibit
larg
sampl
size
per
week
would
provid
reliabl
estim
ihp
midto
late
septemb
low
ratio
iar
preexist
seropreval
age
group
simul
base
case
figur
scenario
serial
crosssect
serosurveil
specimen
per
week
yield
reliabl
estim
ihp
true
seropreval
around
infect
case
becom
seroposit
ill
onset
averag
figur
iar
around
seropreval
around
correspond
iar
seropreval
robust
across
epidem
model
structur
paramet
valu
see
text
figur
perform
serial
crosssect
serosurveil
larg
unaffect
even
sensit
serolog
test
figur
scenario
b
howev
perform
substanti
deterior
specif
serolog
test
drop
figur
scenario
c
preexist
seropreval
increas
figur
scenario
tabl
comparison
estim
ihp
iar
full
model
previou
studi
use
preand
postfirstwav
sera
reliabl
estim
ihp
mainli
limit
soon
could
accur
detect
increas
seropreval
gener
pandem
infect
signal
weak
ie
earli
pandem
stage
accur
detect
would
difficult
test
specif
low
ie
fals
posit
decreas
signaltonois
ratio
preexist
seropreval
close
zero
ie
signaltobackground
ratio
small
limit
could
mitig
increas
titer
cutoff
seroposit
exampl
serolog
followup
virolog
confirm
case
hong
kong
us
found
around
case
develop
mn
titer
seroposit
cutoff
set
mn
titer
preexist
seropreval
serosurvey
respect
increas
cutoff
seroposit
expens
decreas
proport
infect
case
seroposit
h
increas
mean
delay
ill
onset
seroposit
mean
f
seropo
would
slightli
delay
timeli
accur
estim
ihp
figur
scenario
e
perform
serial
crosssect
serosurveil
depend
epidem
dynam
mostli
via
epidem
doubl
time
figur
gener
epidem
doubl
time
longer
serial
crosssect
serosurveil
serum
specimen
per
week
provid
accur
estim
ihp
h
reach
around
rang
doubl
time
perform
serosurveil
larg
similar
delay
start
serosurveil
epidem
seed
vari
given
averag
delay
ill
onset
seroposit
around
would
imposs
serial
crosssect
serosurveil
yield
accur
estim
ihp
nascent
stage
epidem
epidem
doubl
time
short
figur
public
health
need
earli
sever
estim
inform
situat
awar
pandem
respons
thu
highlight
import
aggress
mitig
measur
slow
spread
diseas
earli
stage
pandem
result
suggest
serial
crosssect
serolog
data
avail
weekli
real
time
influenza
pandem
reliabl
estim
iar
ihp
could
obtain
wk
wk
wk
epidem
peak
old
old
old
respect
ratio
iar
preexist
seropreval
signaltobackground
ratio
decreas
age
major
determin
timeli
reliabl
estim
pandem
provid
particular
challeng
point
view
serolog
interpret
caus
viru
subtyp
previous
endem
human
led
presenc
serolog
crossreact
therefor
signific
preexist
seropreval
mn
titer
especi
older
age
group
henc
lack
timeli
reliabl
ihp
estim
retrospect
analysi
would
much
less
problem
pandem
futur
pandem
virus
challeng
pose
serolog
crossreact
may
compar
proport
individu
born
appear
crossreact
antibodi
result
suggest
serial
crosssect
serosurveil
yield
time
accur
estim
iar
sever
preexist
seropreval
need
adjust
near
zero
choos
suffici
high
titer
cutoff
seroposit
given
limit
serolog
test
capac
screen
specimen
mn
titer
exact
antibodi
titer
specimen
perform
serial
crosssect
serosurveil
might
enhanc
exact
titer
avail
incorpor
realtim
estim
ihp
hemagglutin
inhibit
rather
labor
intens
mn
test
use
may
feasibl
pandem
virus
logist
feasibl
perform
serosurveil
may
enhanc
although
mn
test
sensit
specif
confirm
infect
autom
serolog
assay
may
increas
feasibl
largescal
serolog
futur
influenza
pandem
highlight
need
improv
method
rapid
reliabl
assess
transmiss
sever
unfold
infecti
diseas
outbreak
fineberg
et
al
report
perform
pandem
highlight
lack
consist
measur
understand
depict
sever
one
shortcom
respons
call
proper
time
assess
sever
guid
public
health
respons
realtim
transmiss
model
method
previous
devis
estim
iar
sever
base
clinic
surveil
data
without
use
serolog
data
perform
depend
reliabl
underli
transmiss
model
eg
assumpt
data
regard
contact
pattern
age
group
medic
consult
rate
preexist
immun
studi
show
serial
crosssect
serosurveil
could
complement
method
allow
time
accur
realtim
estim
iar
sever
ideal
serosurveil
studi
would
draw
random
sampl
popul
interest
practic
unlik
feasibl
studi
good
agreement
specimen
collect
blood
donor
hospit
outpati
commun
particip
companion
communitybas
cohort
studi
pair
serolog
data
hong
kong
also
gave
similar
seropreval
estim
studi
similar
serolog
studi
demonstr
serosurveil
feasibl
result
inform
could
provid
invalu
data
accur
time
estim
popul
attack
rate
diseas
sever
howev
serosurveil
requir
substanti
laboratori
infrastructur
resourc
pandem
may
compet
concern
laboratori
servic
diagnost
test
vaccin
develop
case
involv
academ
research
center
less
like
pressur
provid
frontlin
diagnost
servic
may
provid
feasibl
solut
total
cost
serolog
studi
around
amount
hong
kong
spent
purchas
vaccin
wherea
inform
provid
studi
instrument
inform
pandem
situat
awar
decis
priorit
vaccin
target
group
hong
kong
addit
reliabl
serolog
assay
serolog
followup
laboratoryconfirm
case
need
conduct
earli
possibl
pandem
order
collect
acuteand
convalescencephas
sera
character
kinet
antibodi
respons
pandem
viru
h
f
seropo
kinet
antibodi
respons
may
strainspecif
exampl
buchi
et
al
analyz
sera
patient
diseas
found
neutral
antibodi
detect
first
week
diseas
onset
mn
titer
wk
diseas
onset
togo
et
al
analyz
sera
seven
individu
experiment
challeng
hong
kong
strain
strain
design
univers
found
neutral
titer
wk
exposur
studi
suggest
serolog
followup
around
case
would
suffici
support
serosurveil
studi
sever
limit
first
serolog
specimen
collect
via
conveni
sampl
blood
donor
hospit
outpati
vaccin
trial
particip
serolog
data
necessarili
provid
repres
descript
seropreval
gener
popul
howev
estim
agespecif
iar
similar
subsequ
mle
ihp
within
true
valu
subsequ
iqrtoml
ratio
less
three
given
epidem
scenario
circl
triangl
indic
reliabl
ihp
estim
obtain
epidem
peak
respect
companion
serolog
studi
hong
kong
base
pairedsera
household
recruit
use
random
digitdi
landlin
second
assum
proport
case
eventu
develop
mn
titer
similar
observ
serolog
followup
virolog
confirm
case
report
symptom
known
whether
asymptomat
case
equal
like
develop
mn
titer
estim
iar
ihp
would
need
revis
new
data
becam
avail
third
pandem
report
delay
clinic
surveil
data
laboratori
capac
avail
serolog
test
subject
consider
uncertainti
model
assum
factor
ratelimit
step
serial
crosssect
serosurveil
number
specimen
need
preexist
seropreval
primari
limit
factor
final
consid
serial
crosssect
design
serosurveil
altern
design
cohortbas
serosurveil
sera
individu
collect
variou
time
point
pandem
iar
infer
seroconvers
rate
ie
use
pair
serolog
perform
latter
design
may
advantag
rel
insensit
preexist
seropreval
obviou
optim
time
collect
sera
cohort
realtim
surveil
pandem
regular
frequent
blood
sampl
individu
unlik
feasibl
plan
compar
serial
crosssect
design
cohortbas
design
futur
studi
conclus
estim
preexist
seropreval
could
adjust
near
zero
around
h
infect
case
reach
seroposit
symptom
onset
averag
serial
crosssect
serosurveil
specimen
per
week
would
allow
reliabl
estim
ihp
iar
soon
h
iar
reach
around
figur
level
test
capac
logist
feasibl
develop
countri
serosurveil
formal
part
pandem
surveil
accur
estim
iar
avail
reliabl
estim
sever
measur
probabl
intens
care
unit
admiss
death
given
infect
easili
obtain
reliabl
sever
estim
obtain
highprior
group
test
capac
could
alloc
group
concentr
effort
gather
data
one
major
citi
affect
earli
cours
pandem
would
potenti
yield
data
global
relev
public
health
strategi
would
use
situat
awar
influenza
pandem
also
pandem
caus
pathogen
eg
futur
sarslik
event
serolog
surveil
consid
updat
plan
influenza
pandem
prepared
respons
pandem
figur
agespecif
proport
individu
antibodi
titer
viral
mn
hong
kong
sinc
june
marker
vertic
bar
indic
mle
confid
interv
weekli
seropreval
estim
use
exact
binomi
method
appli
weekli
serolog
data
data
point
sampl
size
shown
seropreval
old
earli
june
estim
use
blood
sampl
collect
april
particip
pediatr
cohort
studi
ep
figur
number
serum
specimen
would
need
yield
reliabl
estim
ihp
midaugust
influenza
pandem
estim
ihp
full
model
assum
true
ihp
tabl
tick
xaxi
indic
first
day
month
black
circl
indic
median
box
vertic
bar
indic
iqr
confid
interv
ordin
ep
figur
correspond
h
iar
seropreval
randomli
gener
epidem
scenario
text
detail
studi
design
preliminari
analys
editor
summari
background
everi
winter
million
peopl
catch
influenzaa
viral
infect
airwaysand
half
million
die
result
season
epidem
occur
small
frequent
chang
influenza
viru
mean
immun
respons
produc
infect
one
year
viru
provid
partial
protect
next
year
viru
occasion
howev
differ
influenza
viru
emerg
peopl
virtual
immun
virus
start
global
epidem
pandem
kill
million
peopl
recent
influenza
pandem
began
march
mexico
first
case
influenza
caus
new
viru
call
pandem
occur
viru
spread
rapidli
despit
strenuou
effort
nation
intern
public
health
agenc
contain
june
world
health
organ
declar
influenza
pandem
underway
time
announc
pandem
august
kill
peopl
studi
done
earli
influenza
pandem
emerg
pandem
reliabl
estim
transmiss
easili
spread
peopl
sever
proport
infect
peopl
need
hospit
treatment
urgent
need
help
public
health
offici
plan
respons
pandem
advis
public
threat
health
infect
influenza
viru
alway
make
peopl
ill
way
determin
true
size
sever
influenza
outbreak
monitor
occurr
antibodi
protein
made
immun
system
respons
infect
influenza
viru
populationsocal
serolog
surveil
studi
research
develop
method
use
serolog
data
provid
realtim
estim
infect
attack
rate
iar
cumul
occurr
new
infect
popul
infectionhospit
probabl
ihp
proport
affect
individu
need
hospit
influenza
pandem
research
find
research
test
nearli
serum
sampl
collect
hong
kong
first
wave
pandem
antibodi
use
mathemat
approach
call
convolut
estim
iar
ihp
serolog
data
hospit
data
report
serolog
data
avail
weekli
real
time
would
abl
obtain
reliabl
estim
iar
ihp
one
week
one
two
week
three
week
pandem
peak
year
old
year
old
year
old
respect
serolog
surveil
begun
three
week
confirm
commun
transmiss
sampl
size
specimen
per
week
year
old
year
old
year
old
respect
would
suffici
obtain
reliabl
iar
ihp
estim
four
week
pandem
peak
howev
year
old
even
specimen
per
week
would
gener
reliabl
estim
preexist
antibodi
viru
age
group
final
comput
simul
futur
pandem
indic
serolog
surveil
serum
specimen
per
week
would
yield
reliabl
estim
iar
ihp
soon
true
iar
reach
find
mean
find
suggest
serolog
data
togeth
clinic
surveil
data
could
use
provid
reliabl
realtim
estim
iar
sever
emerg
influenza
pandem
although
number
sampl
need
provid
accur
estim
iar
ihp
real
life
may
vari
somewhat
report
limit
design
studi
find
nevertheless
suggest
level
test
capac
need
provid
realtim
estim
iar
ihp
emerg
influenza
pandem
logist
feasibl
develop
countri
moreov
collect
serolog
surveil
data
major
citi
affect
earli
epidem
could
potenti
provid
inform
global
relev
public
health
thu
research
conclud
serolog
monitor
includ
futur
plan
influenza
pandem
prepared
respons
plan
pandem
